Xtant Medical Finalizes $21.4M Asset Sale
Xtant Medical Holdings announced that it has received $10.7M from Companion Spine related to Companion Spine's purchase of Xtant's Coflex assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4M. With this payment, the transactions have now been finalized.
Trade with 70% Backtested Accuracy
Analyst Views on XTNT
About XTNT
About the author
Xtant Medical Launches Next-Gen nanOss Strata™ Synthetic Bone Graft
- Product Innovation: Xtant Medical has launched nanOss Strata™, a synthetic bone graft made from hydroxycarbonapatite (HCA) with higher solubility than traditional materials, aimed at enhancing bioactivity and improving integration with surrounding bone tissue during healing.
- Market Availability: Strata™ is now accessible through Xtant Medical's nationwide distribution network, marking the company's ongoing commitment to innovation in regenerative medicine and aiming to assist surgeons in improving patient surgical outcomes.
- Diverse Product Forms: The product is available in compression-resistant preformed strips and prehydrated moldable grafts, both of which are sterile and highly moldable, allowing for rapid absorption of blood and other biological fluids to meet various surgical needs.
- Strategic Goals: By introducing Strata™, Xtant Medical further solidifies its position in the orthopedic and spinal surgical solutions market, which is expected to drive future revenue growth and enhance market share.
Companion Spine Acquires Paradigm Spine, Expanding Spine Implant Market Reach
- Acquisition Completed: Companion Spine has finalized its acquisition of Paradigm Spine, integrating the Coflex® and CoFix® implants, which is expected to enhance its competitive edge in the spine implant market and increase market share to meet global demand.
- Leadership Integration: The new company will be led by Anthony G. Viscogliosi as Executive Chairman and CEO, with Enrico Sangiorgio as Executive Vice President International, ensuring stability in leadership and capability for market expansion.
- Expanded Product Portfolio: The combined product offerings include various spinal stabilization solutions that cater to a range of conditions, which is anticipated to improve customer satisfaction and strengthen partnerships with distributors.
- Market Strategy Overhaul: Companion Spine will focus on the U.S. market, leveraging its FDA-approved product portfolio to enhance physician awareness of SMART™ technologies, thereby optimizing patient treatment outcomes and driving long-term growth for the company.
Xtant Medical Sells Non-Core Assets for $19.2 Million
- Asset Sale: Xtant Medical has completed the sale of its Coflex® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine for approximately $19.2 million, consisting of $11 million in cash and $8.2 million in short-term seller financing, which is expected to enhance the company's financial liquidity.
- Debt Reduction: The net proceeds from this transaction will be used to reduce long-term debt, enabling Xtant Medical to continue operations without the need for additional external capital, thereby strengthening the company's financial stability.
- Focus on Core Business: CEO Sean Browne stated that this asset sale represents a significant step in allowing the company to concentrate on its core biologics business, driving innovation and improving financial performance, reflecting the company's commitment to strategic transformation.
- Operational Contribution: The operating contributions of these assets and entities will be included in the company's results through the December 1, 2025 date of sale, indicating the company's continued valuation of these businesses prior to the sale.
Xtant Medical Holdings, Inc Q2 Earnings Summary
Earnings Performance: Xtant Medical Holdings, Inc reported earnings of $3.55 million in Q2, a significant improvement from a loss of $3.86 million in the same period last year, with an EPS of $0.02 compared to -$0.03 previously.
Revenue Growth and Guidance: The company achieved revenue of $35.41 million in Q2, up from $29.94 million year-over-year, and provided full-year revenue guidance of $131 - $135 million.
Xtant Medical Announces the Launch of OsteoFactor Pro™
Launch of OsteoFactor Pro™: Xtant Medical Holdings has introduced OsteoFactor Pro™, a growth factor solution designed to enhance bone healing in orthopedic and spine surgeries, featuring a biphasic release profile for effective regeneration.
Company's Commitment to Innovation: This launch positions Xtant as the first company to offer solutions across all five major orthobiologic categories, reflecting its dedication to advancing regenerative medicine and meeting diverse surgical needs.
Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance
Launch of Trivium™: Xtant Medical Holdings, Inc. has introduced Trivium™, a next-generation demineralized bone matrix allograft designed to enhance bone grafting procedures with advanced PureLoc™ Fiber Technology for improved structure, handling, and biological activity.
Commitment to Innovation: The new product aims to provide surgeons with a reliable solution for various surgical applications, supporting optimal healing outcomes while reflecting Xtant Medical's dedication to innovation in regenerative medicine.
Xtant Medical Launches Next-Gen nanOss Strata™ Synthetic Bone Graft
- Product Innovation: Xtant Medical has launched nanOss Strata™, a synthetic bone graft made from hydroxycarbonapatite (HCA) with higher solubility than traditional materials, aimed at enhancing bioactivity and improving integration with surrounding bone tissue during healing.
- Market Availability: Strata™ is now accessible through Xtant Medical's nationwide distribution network, marking the company's ongoing commitment to innovation in regenerative medicine and aiming to assist surgeons in improving patient surgical outcomes.
- Diverse Product Forms: The product is available in compression-resistant preformed strips and prehydrated moldable grafts, both of which are sterile and highly moldable, allowing for rapid absorption of blood and other biological fluids to meet various surgical needs.
- Strategic Goals: By introducing Strata™, Xtant Medical further solidifies its position in the orthopedic and spinal surgical solutions market, which is expected to drive future revenue growth and enhance market share.
Companion Spine Acquires Paradigm Spine, Expanding Spine Implant Market Reach
- Acquisition Completed: Companion Spine has finalized its acquisition of Paradigm Spine, integrating the Coflex® and CoFix® implants, which is expected to enhance its competitive edge in the spine implant market and increase market share to meet global demand.
- Leadership Integration: The new company will be led by Anthony G. Viscogliosi as Executive Chairman and CEO, with Enrico Sangiorgio as Executive Vice President International, ensuring stability in leadership and capability for market expansion.
- Expanded Product Portfolio: The combined product offerings include various spinal stabilization solutions that cater to a range of conditions, which is anticipated to improve customer satisfaction and strengthen partnerships with distributors.
- Market Strategy Overhaul: Companion Spine will focus on the U.S. market, leveraging its FDA-approved product portfolio to enhance physician awareness of SMART™ technologies, thereby optimizing patient treatment outcomes and driving long-term growth for the company.
Xtant Medical Sells Non-Core Assets for $19.2 Million
- Asset Sale: Xtant Medical has completed the sale of its Coflex® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine for approximately $19.2 million, consisting of $11 million in cash and $8.2 million in short-term seller financing, which is expected to enhance the company's financial liquidity.
- Debt Reduction: The net proceeds from this transaction will be used to reduce long-term debt, enabling Xtant Medical to continue operations without the need for additional external capital, thereby strengthening the company's financial stability.
- Focus on Core Business: CEO Sean Browne stated that this asset sale represents a significant step in allowing the company to concentrate on its core biologics business, driving innovation and improving financial performance, reflecting the company's commitment to strategic transformation.
- Operational Contribution: The operating contributions of these assets and entities will be included in the company's results through the December 1, 2025 date of sale, indicating the company's continued valuation of these businesses prior to the sale.
Xtant Medical Holdings, Inc Q2 Earnings Summary
Earnings Performance: Xtant Medical Holdings, Inc reported earnings of $3.55 million in Q2, a significant improvement from a loss of $3.86 million in the same period last year, with an EPS of $0.02 compared to -$0.03 previously.
Revenue Growth and Guidance: The company achieved revenue of $35.41 million in Q2, up from $29.94 million year-over-year, and provided full-year revenue guidance of $131 - $135 million.
Xtant Medical Announces the Launch of OsteoFactor Pro™
Launch of OsteoFactor Pro™: Xtant Medical Holdings has introduced OsteoFactor Pro™, a growth factor solution designed to enhance bone healing in orthopedic and spine surgeries, featuring a biphasic release profile for effective regeneration.
Company's Commitment to Innovation: This launch positions Xtant as the first company to offer solutions across all five major orthobiologic categories, reflecting its dedication to advancing regenerative medicine and meeting diverse surgical needs.
Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance
Launch of Trivium™: Xtant Medical Holdings, Inc. has introduced Trivium™, a next-generation demineralized bone matrix allograft designed to enhance bone grafting procedures with advanced PureLoc™ Fiber Technology for improved structure, handling, and biological activity.
Commitment to Innovation: The new product aims to provide surgeons with a reliable solution for various surgical applications, supporting optimal healing outcomes while reflecting Xtant Medical's dedication to innovation in regenerative medicine.
